IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LICITRA, LISA FRANCESCA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 24.663
NA - Nord America 22.676
AS - Asia 19.249
Continente sconosciuto - Info sul continente non disponibili 3.119
SA - Sud America 2.108
AF - Africa 375
OC - Oceania 216
Totale 72.406
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.565
DE - Germania 10.117
CN - Cina 5.920
SG - Singapore 4.996
GB - Regno Unito 3.817
IT - Italia 3.801
HK - Hong Kong 1.849
BD - Bangladesh 1.773
BR - Brasile 1.507
RU - Federazione Russa 1.422
VN - Vietnam 1.369
FR - Francia 1.123
SE - Svezia 911
IN - India 831
CA - Canada 698
JP - Giappone 694
IE - Irlanda 592
ES - Italia 531
NL - Olanda 438
FI - Finlandia 431
ID - Indonesia 328
KR - Corea 274
TW - Taiwan 241
MX - Messico 214
AU - Australia 202
AR - Argentina 188
TR - Turchia 172
BE - Belgio 165
CH - Svizzera 159
PL - Polonia 153
AT - Austria 147
DK - Danimarca 138
GR - Grecia 129
CO - Colombia 128
EC - Ecuador 102
UA - Ucraina 101
PT - Portogallo 99
IQ - Iraq 88
CI - Costa d'Avorio 86
TH - Thailandia 85
MY - Malesia 82
PH - Filippine 82
HU - Ungheria 74
IL - Israele 74
MA - Marocco 73
ZA - Sudafrica 67
PK - Pakistan 53
RO - Romania 53
IR - Iran 52
CL - Cile 50
SA - Arabia Saudita 48
VE - Venezuela 48
UZ - Uzbekistan 43
CZ - Repubblica Ceca 40
NO - Norvegia 39
EG - Egitto 36
PE - Perù 36
CR - Costa Rica 30
JM - Giamaica 28
TN - Tunisia 28
JO - Giordania 26
AE - Emirati Arabi Uniti 25
HR - Croazia 25
KE - Kenya 24
SK - Slovacchia (Repubblica Slovacca) 24
HN - Honduras 23
RS - Serbia 21
SI - Slovenia 18
EU - Europa 17
GT - Guatemala 17
NP - Nepal 17
PY - Paraguay 17
TT - Trinidad e Tobago 17
LT - Lituania 16
UY - Uruguay 16
NI - Nicaragua 15
DO - Repubblica Dominicana 14
BO - Bolivia 13
NZ - Nuova Zelanda 13
AZ - Azerbaigian 12
BG - Bulgaria 12
EE - Estonia 12
CY - Cipro 11
KZ - Kazakistan 11
LU - Lussemburgo 11
OM - Oman 11
PA - Panama 11
PR - Porto Rico 11
SC - Seychelles 11
DZ - Algeria 10
MD - Moldavia 10
SV - El Salvador 10
SY - Repubblica araba siriana 10
AM - Armenia 8
LB - Libano 8
LV - Lettonia 8
NG - Nigeria 8
AL - Albania 7
AP - ???statistics.table.value.countryCode.AP??? 7
KG - Kirghizistan 7
Totale 69.184
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 8.843
Southend 3.096
Singapore 2.663
Ashburn 2.094
Dallas 1.641
Hong Kong 1.586
San Jose 1.336
Council Bluffs 1.009
Milan 1.000
Fairfield 882
Chandler 825
Santa Clara 812
Beijing 757
Seattle 682
Princeton 657
Wilmington 619
Dublin 583
New York 557
Los Angeles 535
Houston 433
Woodbridge 428
Guangzhou 397
Ho Chi Minh City 373
Lauterbourg 373
Redwood City 364
Nanjing 323
Buffalo 310
Hanoi 310
Cambridge 298
Shanghai 288
Helsinki 285
Tokyo 285
Rome 279
Ann Arbor 266
Des Moines 250
Moscow 250
Bengaluru 249
Jakarta 207
Munich 198
Hefei 194
Seoul 192
São Paulo 186
Chicago 176
Boardman 169
Jinan 166
Tianjin 160
Dearborn 149
London 138
Naples 133
Shenyang 133
Toronto 130
Hangzhou 122
Berlin 118
Columbus 112
Taipei 111
Shenzhen 109
Changsha 107
Duncan 107
Cangzhou 106
San Diego 100
The Dalles 100
Grafing 99
Madrid 98
Nuremberg 97
Phoenix 96
Amsterdam 93
Atlanta 90
Nanchang 87
Wuhan 87
Abidjan 85
Florence 78
Montreal 78
Dong Ket 77
Washington 76
Philadelphia 69
Istanbul 68
Hebei 67
Paris 67
Athens 66
Ottawa 65
Bologna 62
Rio de Janeiro 62
Zhengzhou 62
Chengdu 61
San Francisco 61
Denver 60
Da Nang 58
Turin 58
Vienna 57
Barcelona 56
Jiaxing 56
Boston 50
Mumbai 50
Brussels 49
Genoa 48
Bangkok 47
Hyderabad 47
Warsaw 46
Bogotá 45
Buenos Aires 45
Totale 41.984
Salva come PNG Salva come JPEG
Nome #
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial 4.673
Lenvatinib-induced renal failure : two first-time case reports and review of literature 1.163
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up† 951
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up 732
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) 620
Nivolumab for recurrent squamous-cell carcinoma of the head and neck 578
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations 527
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study 522
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer 492
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer 470
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial 464
A functional gene expression analysis in epithelial sinonasal cancer : Biology and clinical relevance behind three histological subtypes 462
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 448
Adenocarcinoma of ethmoid sinus : an occupational disease = Adenocarcinoma dei seni paranasali : una malattia professionale 447
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 428
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma 423
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach 399
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 383
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: A randomized phase II EORTC trial 382
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 379
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 356
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck : efficacy and safety in CheckMate 141 by age 345
Benefits and Risks of Machine Learning Decision Support System 344
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 342
Italian version of the M.D. Anderson Symptom Inventory - €”Head and Neck Module : linguistic validation 341
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) : health-related quality-of-life results from a randomised, phase 3 trial 325
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic : an international consensus 322
Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients 319
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients 319
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 308
Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma 306
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study 304
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 293
Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma 292
Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use 291
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 283
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project 278
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial 277
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy:ARv7 expression in circulating tumor cells 275
Modelling radiation‐induced salivary dysfunction during IMRT and chemotherapy for nasopharyngeal cancer patients 274
TP53, P14ARF, P16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses 266
Radiotherapy for unresectable sinonasal cancers : dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy 265
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group 263
Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions 262
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies : literature review and consensus 258
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 257
Big Data in Head and Neck Cancer 255
Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients 252
Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy 250
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 246
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper 245
Do not throw the baby out with the bathwater : SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 245
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 245
Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma 244
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer : An Italian validation study 243
Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck 240
Baseline mri-radiomics can predict overall survival in non-endemic ebv-related nasopharyngeal carcinoma patients 240
Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report 239
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials 238
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas : Translational analyses and clinical impact 237
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 234
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma 233
Are Fusion Transcripts in Relapsed/ Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? 227
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 227
The day after De-ESCALaTE and RTOG 1016 trials results 226
Motesanib diphosphate in progressive differentiated thyroid cancer 225
Hope in cancer patients : The relational domain as a crucial factor 224
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 224
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 223
Response of the Istituto Nazionale Tumori of Milan Head & Neck Cancer Unit to the COVID-19 outbreak 223
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 222
Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures 222
T-cell therapy for EBV-associated nasopharyngeal carcinoma : preparative lymphodepleting chemotherapy does not improve clinical results 221
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/ metastatic head and neck squamous cell carcinoma treated with nivolumab 220
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma 219
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis : a randomized, double-blind study 218
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma : a phase II trial of 22 patients 217
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 216
Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma 215
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer 214
Pain management in head and neck cancer patients undergoing chemo-radiotherapy : Clinical practical recommendations 214
Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base' 214
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a nonendemic area 214
Identification of potentially druggable molecular alterations in skin adnexal malignancies 214
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck 212
Head and neck cancer 210
Lung metastasectomy in adenoid cystic cancer : is it worth it? 209
Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy 209
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 208
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study 207
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities 205
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer : a Systematic Review and Meta-Analysis of Aggregate Data 205
Rationale and design of LUX-Head & Neck 1 : a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy 204
Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) 204
Integrative miRNA-Gene expression analysis enables refinement of associated biology and prediction of response to cetuximab in head and neck squamous cell cancer 204
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study 203
Prevalence of Fatigue in Head and Neck Cancer Survivors 203
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy 203
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 202
Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016 202
Totale 34.723
Salva come PNG Salva come JPEG
Categoria #
all - tutte 172.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 172.647
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.395 0 0 392 406 466 364 396 391 469 435 237 839
2022/20234.738 576 359 541 413 429 826 199 246 474 191 272 212
2023/20249.379 200 313 247 268 654 298 1.352 1.202 712 1.228 1.430 1.475
2024/202510.955 1.272 1.711 1.101 1.125 529 412 378 885 553 681 738 1.570
2025/202623.725 1.553 1.037 2.773 1.298 1.915 1.585 2.595 1.493 2.793 1.569 2.456 2.658
2026/20273.367 1.383 1.856 128 0 0 0 0 0 0 0 0 0
Totale 72.406